1Dania Movia*, 2,3 Maroua Benhaddada, 2Jolanda Spadavecchia, 1,4Adriele Prina-Mello*1 LBCAM, Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland
2 CNRS, UMR 7244, NBD-CSPBAT, Laboratoire de Chimie, Structures et Propriétés de Biomatériaux et d’Agents Thérapeutiques Université Sorbonne Paris Nord, Bobigny, France
3 TORSKAL nanoscience, Sainte Clotilde, La Réuinon, France
4 AMBER Centre, CRANN Institute, Trinity College Dublin, Dublin, Ireland

Keywords
Gold nanoparticle
1
; external stimuli; physical stimuli; physically triggered
nanomedicine.
Quote this article as: Movia D, Benhaddada M, Jolanda Spadavecchia J, Prina
-
Mello A, Latest advances in
combining gold nanomaterials with physical stimuli towards new responsive therapeutic and diagnostic strategies,
Precis. Nanomed. 2020 Apr
il;3(2):495
-
524
,
https://doi.org/
10.33218/001c.12650
Abstract
Nanomedicine aims at enhancing treatment efficiency and/or improving diagnostic sensitivity by better controlling several critical parameters, such as tissue targeting and off target toxicity. More recently, advanced nanomedicine products have been developed to achieve spatially and temporally controlled therapy and diagnosis. This review focuses on gold nanomaterials (AuNMs) and alloy/hybrid AuNMs that can be used in stimuli-responsive strategies for therapeutic and diagnostic applications.
Endogenous and/or exogenous stimuli can be used as a trigger for such systems.
Herein, we focus on those activated by exogenous stimuli. Our review starts from one specific externally activated product, Aurolase®, which recently underwent clinical studies.
Further we continue describing a specific physically triggered category, for which the exogeneous stimulus applied induces a structural transformation or modification that is essential for their therapeutic and/or diagnostic action.
Gold nanomaterials are grouped both by the nature of the function they exert (therapeutic or diagnostic) and the stimuli class.

Full paper available here: https://precisionnanomedicine.com/articl...stic-strategies
Corresponding authors: Email: dmovia@tcd.ie; prinamea@tcd.ie;
Full postal address: Lab 0.74,
Trinity Translational
Medicine Institute, Trinity Centre for Health Sciences, James’s Street, D8, Dublin,
Ireland.